Form 4: Lexicon Pharmaceuticals Director Amouyal Reports Stock Transaction

Director Philippe Amouyal reports acquisition of 36,810 shares of Lexicon Pharmaceuticals common stock through vesting of restricted stock units.

Summary

• On May 13, 2025, Philippe Amouyal, a director of Lexicon Pharmaceuticals, reported a transaction involving the company's stock.
• Amouyal acquired 36,810 shares of common stock through the vesting of restricted stock units.
• The price per share for the transaction was $0.
• Following the transaction, Amouyal beneficially owns 285,174 shares of Lexicon Pharmaceuticals common stock.
• The restricted stock units vest 100% on the first anniversary of the grant date and each unit represents one share of common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction. It doesn't inherently indicate positive or negative sentiment.

Positives

• The vesting of restricted stock units indicates that the director is meeting the requirements of their compensation package.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity by a director, which is typical for executive compensation and equity-based awards.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a standard part of executive compensation.

Key Dates

Keywords

Lexicon Pharmaceuticals, Director, Philippe Amouyal, Stock Transaction, Restricted Stock Units, Beneficial Ownership, LXRX